The gut-blood barrier permeability - A new marker in cardiovascular and metabolic diseases?

被引：44

作者：

Ufnal, Marcin ^{[1
]}

Pham, Kinga ^{[1
]}

机构：

[1] Med Univ Warsaw, Dept Expt Physiol & Pathophysiol, Lab Ctr Preclin Res, Warsaw, Poland

来源：

MEDICAL HYPOTHESES | 2017年 / 98卷

关键词：

TRIMETHYLAMINE-N-OXIDE; CHRONIC HEART-FAILURE; INFLAMMATORY BOWEL DISEASES; INTESTINAL BARRIER; TIGHT JUNCTIONS; CROHNS-DISEASE; L-CARNITINE; DYSFUNCTION; MICROBIOTA; RATS;

D O I：

10.1016/j.mehy.2016.11.012

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Recent studies suggest that blood-borne metabolites of gut microbiota, such as trimethylamine N-oxide (TMAO) are involved in the aetiology of cardiovascular diseases and may serve as markers of cardiovascular risk. To enter the bloodstream the microbiota-derived molecules need to pass the gut-blood barrier (GBB). The GBB plays an important role in maintaining organism homeostasis. It is a complex multi-layer system which determines the absorption of nutrients, water and many other substances. The integrity and permeability of the GBB may be impaired in numerous diseases including gastrointestinal, metabolic and cardiovascular diseases. Here, we propose that the evaluation of the GBB permeability may have a significant diagnostic potential in cardiovascular and metabolic diseases. Second, we suggest that the GBB permeability is a variable that confounds diagnostic value of new gut microbiota-derived biomarkers such as TMAO. Therefore, cardiovascular risk assessment requires the evaluation of both TMAO and the GBB permeability. (C) 2016 Elsevier Ltd. All rights reserved.

引用

页码：35 / 37

页数：3

共 38 条

[1] Intestinal permeability - a new target for disease prevention and therapy [J].